Evidence map›Paper›PMID 41769608›Full record

ReviewCureus2026

Multispecies Probiotic Supplementation in Chronic Kidney Disease (CKD): Insights From Indian Nephrology Experts.

Pankaj Beniwal, Manish Singla, Deba Prasad Kar, Vinant Bhargava, Naman Chandra, D K Sinha, Vivek Ruhela, Rathan Jha, Rajesh Joseph, Vishnu Rs and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Pankaj BeniwalNephrology, Sawai Man Singh (SMS) Medical College, Jaipur, IND.
Manish SinglaNephrology, Max Super Speciality Hospital, Mohali, IND.
Deba Prasad KarNephrology, Institute of Medical Sciences (IMS) and Siksha 'O' Anusandhan (SOA) Deemed to be University (SMU), Bhubaneshwar, IND.
Vinant BhargavaNephrology, Sir Ganga Ram Hospital, Delhi, IND.
Naman ChandraNephrology, Nirmal Hospital, Rishikesh, IND.
D K SinhaNephrology, Heritage Hospital, Varanasi, IND.
Vivek RuhelaNephrology, Shri Mahant Indiresh Hospital, Dehradun, IND.
Rathan JhaNephrology, Center for Advanced Research and Excellence (CARE) Hospitals, Hyderabad, IND.
Rajesh JosephNephrology, Believers Church Medical College and Hospital, Thiruvalla, IND.
Vishnu RsNephrology, Sree Uthradom Thirunal (SUT) Hospital, Trivandrum, IND.
Nitin BhosleNephrology, Kidney Ease Clinic, Mumbai, IND.
Kapil MehtaMedical Affairs, JB Pharma, Mumbai, IND.
Sarita BajpaiMedical Affairs, JB Pharma, Mumbai, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) is a progressive condition leading to the accumulation of uremic toxins and systemic complications, eventually resulting in loss of kidney function. One of the major mechanisms behind the CKD complications is gut dysbiosis, a commotion in the gut micro-ecology that aggravates systemic inflammation and worsens the CKD management. Probiotics, through their ability to restore gut micro-ecology, strengthen the intestinal barrier integrity, modulate the immune system, and mitigate systemic inflammation, offer a promising add-on therapy to traditional CKD therapies. Specific probiotic strains, including

Indexed as

chronic kidney disease (ckd)ckd managementgut dysbiosisprobiotics and microbiomeuremic toxins

Identifiers

PMID41769608
PMCPMC12949327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.